NCT02063945.

Methods	Randomised controlled trial, open label
Participants	Children and adolescents with attention deficit/hyperactivity disorder, oppositional defiant disorder or conduct disorder
Interventions	Drug 1: methylphenidate Drug 2: risperidone
Outcomes	Primary outcome measure: change from baseline of aggressive behaviours. The Retrospective Modified Overt Aggression Scale (R‐MOAS) will be used for the assessment of aggressive behaviours and their response to treatment. Time frame: baseline, 2 weeks, 4 weeks, 8 weeks
Notes	ClinicalTrials.gov identifier: NCT02063945: Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders. Open label rather than double blinded according to the ClinicalTrials.gov web site. Likely to end up as an excluded trial. (clinicaltrials.gov/ct2/show/NCT02063945)

ADHD: attention deficit hyperactivity disorder.
 IQ: intelligence quotient.
 IRCT: Iranian Registry of Clinical Trials.
 vs: versus.